CNBX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 15:42):

CNBX Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of cannabinoid-based treatments and therapies for cancer...

Stats
Today's Volume	1.21M
Average Volume	229 272
Market Cap	336 003
EPS	$0 ( 2024-04-14 )
Next earnings date	( $0 ) 2024-07-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0.0100
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2014-07-25	Cannabics Inc.	Buy	18 239 594	COMMON STOCK
2014-06-23	Cannabics Inc.	Buy	14 525 000	Common Stock
2014-05-08	Cannabics Inc.	Buy	20 500 000	Common Stock
2014-05-08	Mills Thomas E	Sell	20 500 000	common stock
2014-04-25	Mills Thomas E	Buy	20 500 000	common stock

INSIDER POWER
0.00
Last 15 transactions
Buy: 135 764 594 \| Sell: 73 500 000

Cannabics Pharmaceuticals Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cannabics Pharmaceuticals Financials

Annual	2023
Revenue:	$410 165
Gross Profit:	$248 104 (60.49 %)
EPS:	$-0.420

FY	2023
Revenue:	$410 165
Gross Profit:	$248 104 (60.49 %)
EPS:	$-0.420

FY	2022
Revenue:	$29 958.00
Gross Profit:	$-168 569 (-562.68 %)
EPS:	$-3.08

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.0200

Financial Reports:

No articles found.

Cannabics Pharmaceuticals

CNBX Pharmaceuticals Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of cannabinoid-based treatments and therapies for cancer. Its lead product candidate is RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer. The company is also developing various drug candidates, including PLP-33 for the treatment of lateral spreading or sessile, and colorectal polyps during colonoscopy; BRST-33 to treat breast cancer; MLN-33 for the treatment of Melanoma; and PRST-33 to treat prostate cancer. In addition, it develops Cannabics SR, a lipid-based capsule containing a standardized formulation of cannabinoids for the treatment of cancer anorexia-cachexia syndrome; and Cannabics CDx, an ex-vivo drug sensitivity test. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland. CNBX Pharmaceuticals Inc. is a subsidiary of Cannabics Inc.